Skip to main content
SpringerLink
Log in

Patterns of Recurrence After Surgery for Pancreatic Cancer

  • Chapter
  • First Online:
Textbook of Pancreatic Cancer

Abstract

An accurate understanding of pancreatic cancer recurrence after seemingly successful surgery is essential for the development of novel strategies that can improve outcomes for patients. Currently, disease recurrence occurs in up to 80–90% of patients after resection and is the main cause of disease-specific mortality. The main recurrence patterns following resection for pancreatic cancer include hepatic metastases, peritoneal carcinomatosis, locoregional recurrence and pulmonary metastases. More than 75% of recurrences occur at distant sites, demonstrating that most patients with pancreatic cancer should be presumed to have systemic spread at the time of resection. The specific recurrence locations have different predictive factors and demonstrate distinct survival outcomes. Hepatic recurrence, peritoneal carcinomatosis and multiple-site recurrence occur early and are associated with relatively limited overall survival. On the other hand, isolated local or pulmonary recurrence seem to be associated with relatively favorable survival. Future studies that take into account the diverse behaviours of disease recurrence could contribute to improved prognosis stratification, new targets of treatment, and a more patient-tailored approach for patients with pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, et al. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318–48.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Paniccia A, Hosokawa P, Henderson W, Schulick RD, Edil BH, McCarter MD, et al. Characteristics of 10-year survivors of pancreatic ductal adenocarcinoma. JAMA Surg. 2015;150:701–10.

    Article  PubMed  Google Scholar 

  3. Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395–406.

    Article  CAS  PubMed  Google Scholar 

  4. Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH, et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2018;267:936–45.

    Article  PubMed  Google Scholar 

  5. Cannistrà M, Ruggiero M, Zullo A, Serafini S, Grande R, Nardo B. Metastases of pancreatic adenocarcinoma: a systematic review of literature and a new functional concept. Int J Surg. 2015;21:S15–21.

    Article  PubMed  Google Scholar 

  6. Fortner JG. Regional pancreatectomy for cancer of the pancreas, ampulla, and other related sites. Tumor staging and results. Ann Surg. 1984;199:418–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kayahara M, Nagakawa T, Ueno K, Ohta T, Takeda T, Miyazaki I. An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer. 1993;72:2118–23.

    Article  CAS  PubMed  Google Scholar 

  8. Johnstone PA, Sindelar WF. Patterns of disease recurrence following definitive therapy of adenocarcinoma of the pancreas using surgery and adjuvant radiotherapy: correlations of a clinical trial. Int J Radiat Oncol Biol Phys. 1993;27:831–4.

    Article  CAS  PubMed  Google Scholar 

  9. Blastik M, Plavecz E, Zalatnai A. Pancreatic carcinomas in a 60-year, institute-based autopsy material with special emphasis of metastatic pattern. Pancreas. 2011;40:478–80.

    Article  PubMed  Google Scholar 

  10. Kamisawa T, Isawa T, Koike M, Tsuruta K, Okamoto A. Hematogenous metastases of pancreatic ductal carcinoma. Pancreas. 1995;11:345–9.

    Article  CAS  PubMed  Google Scholar 

  11. Nagai H, Kuroda A, Morioka Y. Lymphatic and local spread of T1 and T2 pancreatic cancer. A study of autopsy material. Ann Surg. 1986;204:65–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Lisa JR, Trinidad S, Rosenblatt MB. Pulmonary manifestations of carcinoma of the pancreas. Cancer. 1964;17:395–401.

    Article  CAS  PubMed  Google Scholar 

  13. Groot VP, Blair AB, Gemenetzis G, Ding D, Burkhart RA, van Oosten AF, et al. Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival. HPB (Oxford). 2019;21:998–1008.

    Article  Google Scholar 

  14. Tanaka M, Mihaljevic AL, Probst P, Heckler M, Klaiber U, Heger U, et al. Meta-analysis of recurrence pattern after resection for pancreatic cancer. Br J Surg. 2019;106:1590–601.

    Article  CAS  PubMed  Google Scholar 

  15. Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg. 2006;10:511–8.

    Article  PubMed  Google Scholar 

  16. Iacobuzio-donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27:1806–13.

    Google Scholar 

  17. Gemenetzis G, Groot VP, Blair AB, Laheru DA, Zheng L, Narang AK, et al. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg. 2019;270:340–7.

    Article  PubMed  Google Scholar 

  18. Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, et al. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol. 2020;38:1763–73.

    Google Scholar 

  19. Schorn S, Demir IE, Samm N, Scheufele F, Calavrezos L, Sargut M, et al. Meta-analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma. BJS Open. 2018;2:52–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Groot VP, Blair AB, Gemenetzis G, Ding D, Burkhart RA, Yu J, et al. Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. Eur J Surg Oncol. 2019;45:1674–83.

    Article  PubMed  Google Scholar 

  21. Jang JY, Han Y, Lee H, Kim SW, Kwon W, Lee KH, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg. 2018;268:215–22.

    Article  PubMed  Google Scholar 

  22. Blair AB, Yin L-D, Pu N, Yu J, Groot VP, Rozich NS, et al. Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands A Nationwide Analysis. Ann Surg. November 2019 [Epub Ahead of Print]. https://doi.org/10.1097/SLA.0000000000003570.

  23. Hashemi-Sadraei N, Gbolahan OB, Salfity H, O’Neil B, House MG, Shahda S. Clinical characteristics of patients experiencing pathologic complete response following neoadjuvant therapy for borderline resectable/locally advanced pancreatic adenocarcinoma. Am J Clin Oncol. 2018;41:982–5.

    Article  PubMed  Google Scholar 

  24. He J, Blair AB, Groot VP, Javed AA, Burkhart RA, Gemenetzis G, et al. Is a pathological complete response following neoadjuvant chemoradiation associated with prolonged survival in patients with pancreatic cancer? Ann Surg. 2018;268:1–8.

    Article  PubMed  Google Scholar 

  25. Katz MH, Ou FS, Herman JM, Ahmad SA, Wolpin B, Marsh R, et al. Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer. 2017;17:505.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Strijker M, Chen JW, Mungroop TH, Jamieson NB, van Eijck CH, Steyerberg EW, et al. Systematic review of clinical prediction models for survival after surgery for resectable pancreatic cancer. Br J Surg. 2019;106:342–54.

    Article  CAS  PubMed  Google Scholar 

  27. van Roessel S, Strijker M, Steyerberg EW, Groen JV, Mieog JS, Groot VP, et al. International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer. Eur J Surg Oncol. 2020;46:796–803.

    Article  PubMed  Google Scholar 

  28. Van Roessel S, Kasumova GG, Verheij J, Najarian RM, Maggino L, De Pastena M, et al. International validation of the eighth edition of the American Joint Committee on Cancer (AJCC) TNM staging system in patients with resected pancreatic cancer. JAMA Surg. 2018;153:e183617.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Wu W, He J, Cameron JL, Makary M, Soares K, Ahuja N, et al. The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma. Ann Surg Oncol. 2014;21:2873–81.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Oba A, Croce C, Hosokawa P, Meguid C, Torphy RJ, Al-Musawi MH, et al. Prognosis based definition of resectability in pancreatic cancer. Ann Surg. 2020; https://doi.org/10.1097/SLA.0000000000003859.

  31. Tani M, Kawai M, Miyazawa M, Hirono S, Ina S, Nishioka R, et al. Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma. Langenbecks Arch Surg. 2009;394:249–53.

    Article  PubMed  Google Scholar 

  32. Asiyanbola B, Gleisner A, Herman JM, Choti MA, Wolfgang CL, Swartz M, et al. Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio. J Gastrointest Surg. 2009;13:752–9.

    Article  PubMed  Google Scholar 

  33. Parikh AA, Maiga A, Bentrem D, Squires MH, Kooby DA, Maithel SK, et al. Adjuvant therapy in pancreas cancer: does it influence patterns of recurrence? J Am Coll Surg. 2016;222:448–56.

    Article  PubMed  Google Scholar 

  34. Shibata K, Matsumoto T, Yada K, Sasaki A, Ohta M, Kitano S. Factors predicting recurrence after resection of pancreatic ductal carcinoma. Pancreas. 2005;31:69–73.

    Article  PubMed  Google Scholar 

  35. Kovač JD, Mayer P, Hackert T, Klauss M. The time to and type of pancreatic cancer recurrence after surgical resection: is prediction possible? Acad Radiol. 2019;26:775–81. http://www.ncbi.nlm.nih.gov/pubmed/30254003.

    Article  PubMed  Google Scholar 

  36. Jones RP, Psarelli EE, Jackson R, Ghaneh P, Halloran CM, Palmer DH, et al. Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: a secondary analysis of the ESPAC-4 randomized adjuvant chemotherapy trial. JAMA Surg. 2019;154:1038–48.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Sugiura T, Uesaka K, Mihara K, Sasaki K, Kanemoto H, Mizuno T, et al. Margin status, recurrence pattern, and prognosis after resection of pancreatic cancer. Surgery. 2013;154:1078–86.

    Article  PubMed  Google Scholar 

  38. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003;237:74–85.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Cleary SP, Gryfe R, Guindi M, Greig P, Smith L, Mackenzie R, et al. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg. 2004;198:722–31.

    Article  PubMed  Google Scholar 

  40. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–79.

    Article  CAS  PubMed  Google Scholar 

  41. Kuhlmann KF, De Castro SM, Wesseling JG, Ten Kate FJ, Offerhaus GJ, Busch OR, et al. Surgical treatment of pancreatic adenocarcinoma: actual survival and prognostic factors in 343 patients. Eur J Cancer. 2004;40:549–58.

    Article  CAS  PubMed  Google Scholar 

  42. Daamen LA, Groot VP, Heerkens HD, Intven MPW, van Santvoort HC, Molenaar IQ. Systematic review on the role of serum tumor markers in the detection of recurrent pancreatic cancer. HPB (Oxford). 2018;20:297–304.

    Article  Google Scholar 

  43. Poruk KE, Gay DZ, Brown K, Mulvihill JD, Boucher KM, Scaife CL, et al. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med. 2013;13:340–451.

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Kim TH, Han SS, Park SJ, Lee WJ, Woo SM, Yoo T, et al. CA 19-9 level as indicator of early distant metastasis and therapeutic selection in resected pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011;81:e743–8.

    Article  CAS  PubMed  Google Scholar 

  45. Sugiura T, Uesaka K, Kanemoto H, Mizuno T, Sasaki K, Furukawa H, et al. Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma. J Gastrointest Surg. 2012;16:977–85.

    Article  PubMed  Google Scholar 

  46. Nishio K, Kimura K, Amano R, Yamazoe S, Ohrira G, Nakata B, et al. Preoperative predictors for early recurrence of resectable pancreatic cancer. World J Surg Oncol. 2017 Jan;15:16.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Hadano N, Murakami Y, Uemura K, Hashimoto Y, Kondo N, Nakagawa N, et al. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer. Br J Cancer. 2016;115:59–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Bernard V, Kim DU, San Lucas FA, Castillo J, Allenson K, Mulu FC, et al. Circulating nucleic acids associate with outcomes of patients with pancreatic cancer. Gastroenterology. 2018;156:108–18.

    Article  PubMed  Google Scholar 

  49. Gemenetzis G, Groot VP, Yu J, Ding D, Teinor JA, Javed AA, et al. Circulating tumor cells dynamics in pancreatic adenocarcinoma correlate with disease status. Ann Surg. 2018;268:408–20.

    Article  PubMed  Google Scholar 

  50. Groot VP, Mosier S, Javed AA, Teinor JA, Gemenetzis G, Ding D, et al. Circulating tumor DNA as a clinical test in resected pancreatic cancer. Clin Cancer Res. 2019;25:4973–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol. 2018;36:1631–41.

    Article  CAS  PubMed  Google Scholar 

  52. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg. 1997;21:195–200.

    Article  CAS  PubMed  Google Scholar 

  53. Van den Broeck A, Sergeant G, Ectors N, Van Steenbergen W, Aerts R, Topal B. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol. 2009;35:600–4.

    Article  PubMed  Google Scholar 

  54. Suenaga M, Fujii T, Kanda M, Takami H, Okumura N, Inokawa Y, et al. Pattern of first recurrent lesions in pancreatic cancer: hepatic relapse is associated with dismal prognosis and portal vein invasion. Hepatogastroenterology. 2014;61:1756–61.

    PubMed  Google Scholar 

  55. Zhang Y, Frampton AE, Kyriakides C, Bong JJ, Habib N, Ahmad R, et al. Loco-recurrence after resection for ductal adenocarcinoma of the pancreas: predictors and implications for adjuvant chemoradiotherapy. J Cancer Res Clin Oncol. 2012;138:1063–71.

    Article  CAS  PubMed  Google Scholar 

  56. Groot VP, Gemenetzis G, Blair AB, Ding D, Javed AA, Burkhart RA, et al. Implications of the pattern of disease recurrence on survival following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2018;25:2475–83.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Yamamoto Y, Ikoma H, Morimura R, Konishi H, Murayama Y, Komatsu S, et al. Optimal duration of the early and late recurrence of pancreatic cancer after pancreatectomy based on the difference in the prognosis. Pancreatology. 2014;14:524–9.

    Article  PubMed  Google Scholar 

  58. Groot VP, Gemenetzis G, Blair AB, Rivero-Soto RJ, Yu J, Javed AA, et al. Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. Ann Surg. 2019;269:1154–62.

    Article  PubMed  Google Scholar 

  59. Papavasiliou P, Hoffman JP, Cohen SJ, Meyer JE, Watson JC, Chun YS. Impact of preoperative therapy on patterns of recurrence in pancreatic cancer. HPB (Oxford). 2014;16:34–9.

    Article  Google Scholar 

  60. Lovecek M, Skalicky P, Chudacek J, Szkorupa M, Svebisova H, Lemstrova R, et al. Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: retrospective study and review of the literature. World J Gastroenterol. 2017;23:6420–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Zheng B, Ohuchida K, Yan Z, Okumura T, Ohtsuka T, Nakamura M. Primary recurrence in the lung is related to favorable prognosis in patients with pancreatic cancer and postoperative recurrence. World J Surg. 2017;41:2858–66.

    Article  PubMed  Google Scholar 

  62. Kim S, Itchins M, Arena J, Nahm C, Pavlakis N, Clarke S, et al. Patterns and determinants of recurrence for pancreatic ductal adenocarcinoma after resection. J Pancreas. 2017;18:458–64.

    Google Scholar 

  63. Groot VP, Daamen LA, Hagendoorn J, Borel Rinkes IHM, van Santvoort HC, Molenaar IQ. Use of imaging during symptomatic follow-up after resection of pancreatic ductal adenocarcinoma. J Surg Res. 2018;221:152–60.

    Article  PubMed  Google Scholar 

  64. Boone BA, Zeh HJ, Mock BK, Johnson PJ, Dvorchik I, Lee K, et al. Resection of isolated local and metastatic recurrence in periampullary adenocarcinoma. HPB (Oxford). 2014;16:197–203.

    Article  Google Scholar 

  65. Groot VP, Wolfgang CL, He J. ASO author reflections: do distinct patterns of recurrence impact the prognosis of patients with resected pancreatic ductal adenocarcinoma? Ann Surg Oncol. 2018;25:806–7.

    Article  PubMed  Google Scholar 

  66. Wangjam T, Zhang Z, Zhou XC, Lyer L, Faisal F, Soares KC, et al. Resected pancreatic ductal adenocarcinomas with recurrence limited in lung have a significantly better prognosis than those with other recurrence patterns. Oncotarget. 2015;6:36903–10.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Latil A, Bieche I, Chene L, Laurendeau I, Berthon P, Cussenot O, et al. Gene expression profiling in clinically localized prostate cancer: a four-gene expression model predicts clinical behavior. Clin Cancer Res. 2003;9:5477–85.

    CAS  PubMed  Google Scholar 

  68. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A. 2004;101:811–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Takeno A, Takemasa I, Seno S, Yamasaki M, Motoori M, Miyata H, et al. Gene expression profile prospectively predicts peritoneal relapse after curative surgery of gastric cancer. Ann Surg Oncol. 2010;17:1033–42.

    Article  PubMed  Google Scholar 

  70. Groot VP, Daamen LA, Hagendoorn J, Borel Rinkes IH, Busch OR, van Santvoort HC, et al. Current strategies for detection and treatment of recurrence of pancreatic ductal adenocarcinoma after resection: a nationwide survey. Pancreas. 2017;46:e73–5.

    Article  PubMed  Google Scholar 

  71. Daamen LA, Groot VP, Intven MP, Besselink MG, Busch OR, Groot Koerkamp B, et al. Postoperative surveillance of pancreatic cancer patients. Eur J Surg Oncol. 2019;45:1770–7.

    Article  CAS  PubMed  Google Scholar 

  72. Groot VP, van Santvoort HC, Rombouts SJE, Hagendoorn J, Borel Rinkes IH, van Vulpen M, et al. Systematic review on the treatment of isolated local recurrence of pancreatic cancer after surgery; re-resection, chemoradiotherapy and SBRT. HPB (Oxford). 2017;19:83–92.

    Article  Google Scholar 

  73. Ryan JF, Groot VP, Rosati LM, Hacker-Prietz A, Narang AK, McNutt TR, et al. Stereotactic body radiation therapy for isolated local recurrence after surgical resection of pancreatic ductal adenocarcinoma appears to be safe and effective. Ann Surg Oncol. 2018;25:280–9.

    Article  PubMed  Google Scholar 

  74. Kim YI, Song KB, Lee YJ, Park KM, Hwang DW, Lee JH, et al. Management of isolated recurrence after surgery for pancreatic adenocarcinoma. Br J Surg. 2019;106:898–909.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, UMC Utrecht Cancer Center, Utrecht University, Utrecht, The Netherlands

    Vincent P. Groot, Lois A. Daamen & I. Quintus Molenaar

  2. Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Vincent P. Groot, Jin He & Christopher L. Wolfgang

  3. Department of Radiation Oncology, UMC Utrecht Cancer Center, Utrecht University, Utrecht, The Netherlands

    Lois A. Daamen

  4. Department of Surgery, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, Utrecht University, Utrecht, The Netherlands

    I. Quintus Molenaar

Authors
  1. Vincent P. Groot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lois A. Daamen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jin He
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christopher L. Wolfgang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. Quintus Molenaar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vincent P. Groot .

Editor information

Editors and Affiliations

  1. Stavanger University Hospital, The University of Bergen, Bergen, Norway

    Kjetil Søreide

  2. Chirurgie (VTT), Innsbruck Medical University, Innsbruck, Tirol, Austria

    Stefan Stättner

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Groot, V.P., Daamen, L.A., He, J., Wolfgang, C.L., Molenaar, I.Q. (2021). Patterns of Recurrence After Surgery for Pancreatic Cancer. In: Søreide, K., Stättner, S. (eds) Textbook of Pancreatic Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-53786-9_74

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-53786-9_74

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-53785-2

  • Online ISBN: 978-3-030-53786-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation